Bayer CropScience and FuturaGene sign license agreement for drought tolerance technology in cotton
Bayer CropScience and FuturaGene PLC have entered into a license agreement for a drought tolerance technology. The agreement grants Bayer CropScience exclusive worldwide rights to utilize a FuturaGene drought tolerance technology in cotton. FuturaGene will receive an upfront license fee, followed by development milestone payments and trait royalties on sales of cotton seeds incorporating this technology. Further financial details were not disclosed.
The technology licensed to Bayer is intended to protect the yield of cotton plants when they are subjected to drought. Drought is one of the principal environmental limits of crop yield as it hampers the cultivation of crops on more than 40 percent of the earth’s land surface, posing a serious threat to global agricultural production and food supplies.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Drosophila_embryogenesis
Crucell HIV Vaccine: Promising Preliminary Results Phase I Study
Patient safety and risk management a priority for EU states

Seeing memories being made
Oncoethix starts Phase 1b Trials of OTX015 in the Treatment of Advanced Solid Tumors and Glioma
Epratuzumab data from phase IIb EMBLEM study presented at 9th International Congress on Systemic Lupus Erythematosus
AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis
Immunoglobulin_superfamily
Merck Serono Commits € 1.2 million to the Grant for Fertility Innovation for 2015/16 - Globally, six projects receive funding from this grant cycle
List_of_medical_abbreviations
